Shots: Merck KGaA to receive upfront, milestones, and royalties on net sales. Vertex to get exclusive license rights for Merck’s two DNA-dependent protein kinase (DNA-PK) inhibitors, M9831 (formerly known as […]readmore
Tags : DNA-PK Inhibitors